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share the work provObjective: To determine cost functions that describe the dynamics of costs of HIV
treatment and care inGhana by CD4þ cell count at treatment initiation and over time on
antiretroviral therapy (ART).
Design: We used detailed longitudinal healthcare utilization data from clinical health
records of HIV-infected patients at seven Ghanaian ART clinics to estimate cost
functions of treatment and care by CD4þ cell count at treatment initiation and time
on ART.
Methods: We developed two linear regression models; one with individual random
effects to determine the relationship between CD4þ cell count at ART initiation and
costs of treatment and care, and onewith individual fixed effects to determine the causal
effect of time in care on costs of treatment and care.
Results: Costs for treatment and care were lowest (7.9 US$) for patients with CD4þ
cell counts of at least 350 cells/ml at ART initiation, compared with patients with 50
cells/ml or less at ART initiation, yet the difference was not significant. The per-patient
costs peaked during the first 6 months on ART at 112.6 US$, and significantly decreased
by 70% after 4 years on treatment.
Conclusion: Our findings show that an accurate analysis of resource needs of HIV
treatment and care should take into account that healthcare costs for HIV-infected
people are dynamic rather than constant. The cost functions derived from our study are
valuable input for cost-effectiveness analyses and research allocation exercises for HIV
treatment in sub-Saharan Africa.
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Of the estimated 36.7 million individuals living with HIV
worldwide in 2015, approximately 70% resided in sub-
Saharan Africa (SSA) [1]. Nevertheless, in contrast to
most countries in Eastern and Southern Africa, Western
African countries are generally facing relatively low HIV
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eligibility at CD4þ cell counts of 350 cell/ml or less [4]. In
2013, the WHO expanded the recommended ART
eligibility to 500 cells/ml or less [5], and further to
recommending treatment at any CD4þ cell count in 2015
[6]. Increased treatment coverage and expanded eligibility
are both important measures towards combating the HIV
epidemic, yet they require an immediate increase in
delegated funding [7].
In order for countries like Ghana to make decisions on
ART delivery, comprehensive data on the costs of HIV
treatment and care are essential [8]. These costs are
dynamic, as the resource needs for monitoring and
treating patients varies with disease stage. Disease stage
varies both across individuals at treatment initiation
[9–13] and may change within individuals through
recovery as a result of effective treatment [14–16].
Accurately estimating per-patient costs of HIV treat-
ment and care thus requires analysis of longitudinal
observations of HIV-infected patients on ART to
determine cost functions over time. However, most
costing studies of HIV treatment and care in SSA are
cross-sectional and only determined the costs of HIV
treatment and care as a fixed per-patient cost, or cross-
sectionally compared patients at different stages of care
[15,17,18]. There are three studies that performed a
longitudinal analysis: Leisegang et al. [16] described the
costs of HIV treatment and care by using data from
private-sector ART delivery in Southern Africa,
Kimaro et al. [19] estimated the costs of HIV treatment
and care in the 1st year of treatment for HIV-infected
individuals at an advanced disease stage in Tanzanian
public health centres and Harling and Wood [14]
assessed the change in healthcare costs over time on
ART for HIV-infected patients in a nongovernmental-
organization-supported public sector ART programme
in South Africa. As none of these studies corrected for
unobserved confounding, the validity of the causal
inference and generalizability to other settings is
limited. A comprehensive costing study of HIV
treatment and care, which can control for all
unobserved time-constant confounding, and thus
identify causal cost functions by time on treatment,
is highly needed. The only available data on the cost of
ART in Ghana to date is limited to interviews collected
from health staff at healthcare facilities who were asked
to estimate the costs of elements of HIV treatment and
care [20].
We determined the costs of HIV treatment and care in
Ghana by CD4þ cell count at treatment initiation and
time on ART by using detailed healthcare utilization data
from clinical health records of HIV-infected patients at
seven, mainly public-sector, Ghanaian ART clinics. The
longitudinal nature of our data allowed us to accurately
estimate cost functions of HIV treatment and care
over time.Methods
Setting
During September 2013, we collected data from clinical
health records at seven ART clinics in Ghana at different
levels of care. These clinics are vertically organized and
purely concerned with HIV care, yet they are located on
the premises of larger healthcare facilities. Two clinics
were located at district hospitals, two at regional
hospitals, one at a teaching hospital, one at a mission
hospital and one at a private hospital. We specifically
chose these clinics as these roughly represent the scope
of care of ART delivery in Ghana. Five of the ART
clinics were located in the Greater Accra region and two
in the Eastern region.
Each clinic is required to have at least six healthcare
workers trained on ART [21] including a doctor, a
nurse, a counsellor and a pharmacist [22]. Ghanaian
treatment guidelines state that patients should be
followed up every 14 days in the first month after
ART initiation, then monthly for the second and third
month and every two to three months in the subsequent
time in care [22].
Healthcare utilization data
At each clinic, research assistants were asked to randomly
collect 50 clinical health records. The inclusion of
clinical health records was based on two criteria: (1)
the patient was aged 15 years or older at first registration
in the clinic; and (2) the patient initiated ART during
2009, 2010 or 2011. The clinical health records
exclusively hold information from visits at the respective
ART clinics, and do not record information about
additional care that HIV-infected patients may have
received elsewhere.
We collected all healthcare utilization reported in
the clinical health records at every appointment for all
patients. Utilization included outpatient visits, inpati-
ents stays, diagnostic tests and routine monitoring,
antiretroviral drugs prescribed and non-antiretroviral
drugs prescribed for opportunistic infections or other
comorbidities. CD4þ cell count at treatment initiation
was defined as the last documented CD4þ cell count
prior to or on the date of ART initiation. Data
were collected from first date of registration to
December 2012.
Unit costs
We determined costs from a healthcare provider’s
perspective; patient-related costs such as lost wages,
transportation costs and out-of-pocket expenses were
not included. All unit costs were obtained from local
sources, including a healthcare facility independent of
this study but part of the Greater Accra Regional
Health Directorate, henceforth referred to as the
independent healthcare facility. The independent
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proxy of the different types of healthcare facilities
included in the study.
Costs for outpatient visits consisted the salary for involved
healthcare personnel during patient consultations. Salary
structures were obtained from the Ghana Health Services
(GHS), the governmental entity in charge of establishing
pay structures for public hospitals in consultation with the
Ministry of Health and the Ministry of Finance and
Economic Planning. The salary structure for the private
hospital was obtained directly from the healthcare facility.
We retrieved costs for inpatient stays from the indepen-
dent healthcare facility including costs for hospitalization,
food, sanitation and documentation.
The unit costs for diagnostic tests and routine monitoring
consisted of a combination of costs for the necessary
testing equipment and salary for the time required for a
laboratory technician to perform each test. The estimated
costs of testing equipment were primarily collected from
one of the providers of diagnostic services for govern-
mental hospitals in Ghana, and when not available, were
obtained from the independent healthcare facility.
Costs of antiretroviral drugs were obtained from the
National AIDS Control Programme. We retrieved
medication costs for all non-antiretroviral drugs recorded
in the medical health records from the National Health
Insurance Authority (NHIA) [23]. If unobtainable from
the NHIA, medication costs were supplemented with
data from the independent healthcare facility and a private
pharmaceutical company. The costs of tuberculosis
medication were obtained from the Global Drug Facility
Product Catalogue [24].
All costs were corrected for inflation by using the health-
specific consumer price index [25,26] with December
2012 as the reference period. All monetary values were
converted to US dollars (US$) for the analysis by using the
average exchange rate for the 31 December 2012 at a rate
of 1 US$ to 1.899 Ghana Cedi [27].
We had to make several assumptions to translate observed
healthcare utilization into costs, for example on-time
allocation for healthcare personnel for specific tasks and of
the pill count in prescriptions recorded in the clinical
health records. All cost values and sources, as well as a
detailed description of all assumptions made in the cost
analysis are given in the Supplementary document,
http://links.lww.com/QAD/B143.
Analysis
In this study, we defined the costs of HIV treatment and
care as the total costs incurred for an individual patient
in a 6-month period of care. For each patient visit at
the ART clinics, we first multiplied all healthcare
utilization reported in the clinical health records withthe corresponding unit costs to determine the costs of
HIV care and treatment data. Next, we stratified the
data by CD4þ cell count at ART initiation (eight
categories: 50, 51–100, 101–150, 151–200, 201–
250, 251–300, 301–350, 351 cells/ml) and by the
time in care (in 6-month intervals). For patients with
missing information on CD4þ cell count at treatment
initiation (n¼ 40), values were imputed using a
multivariate normal model. This model uses a data
augmentation algorithm to fill in missing data by
drawing from a multivariate normal distribution, given
the observed data [28]. For this study, the distribution
was based on the first 6 months after ART initiation, as
this was the period with most observations.
To determine the relationship between CD4þ cell count
at ART initiation and costs of treatment and care for HIV-
infected patients in Ghana, we developed a multivariable
linear regression model with individual random effects.
The analysis controls for dependency of repeated
observations within the same individuals. Costs of HIV
treatment and care were analysed as the dependent
variable and CD4þ cell count at treatment initiation as the
independent variable. The analysis only included costs
that were incurred after ART initiation.
To determine the effect of time in care on costs of HIV
treatment and care in Ghana, we developed a linear
regression model with individual fixed effects to control
for all unobserved time-constant confounding. By
including individual fixed effects within regression
models, we can correct for all characteristics of each
individual that are constant over the observational
period (e.g. sex, condition of the patient at the start of
treatment, patient preferences for care, etc). Further-
more, this approach allows us to correct for selection
effects, as the characteristics of patients observed only
in the 1st year of treatment might not necessarily be
comparable with those already on treatment for 3 to 4
years. The first 6 months after ART initiation were
used as the reference period as this period contained
observations on healthcare utilization in all patients.
Costs of HIV treatment and care were analysed as the
dependent variable and time since treatment initiation
as the independent variable. All analyses were
performed by using Stata version 1.2.1 (StataCorp,
College Station, Texas, USA) and Microsoft Excel
(Redmond, Washington, USA).
Sensitivity analysis
We performed univariate sensitivity analyses on all
assumptions made in our main analysis. First, we assessed
the impact of the imputations for missing CD4þ cell
count values at ART initiation by repeating the analysis,
excluding cases missing CD4þ cell count values. Second,
we determined sensitivity of assumptions underlying the
cost calculations in the main analysis of outpatient visits,
inpatient stays, diagnostic tests and routine monitoring,
2282 AIDS 2017, Vol 31 No 16
Table 1. Baseline characteristics of antiretroviral therapy clinics and patients from Ghana included in the study.
Data characteristics
Number of ART clinics
By type
District 2
Regional 2
Mission 1
Teaching 1
Private 1
Total 7
By location
Greater Accra region 5
Eastern region 2
Patient characteristics
Number of patients 352a
Females 242 (69%)
Males 110 (31%)
Time in care (months)
Mean time in care (IQR) 31.99 (30.77–33.23)
Mean follow-up time after ART initiation (IQR) 28.45 (27.38–29.52)
CD4þ cell count at treatment initiation (by year of ART initiation) 2009 2010 2011
50 cells/ml 20 23 21
51–100 cells/ml 15 24 11
101–150 cells/ml 13 15 12
151–200 cells/ml 16 12 14
201–250 cells/ml 12 8 14
251–300 cells/ml 18 14 15
301–350 cells/ml 9 16 11
351 cells/ml 12 9 18
Total 115 121 116
ART, antiretroviral therapy.
aWe aimed to collect 50 clinical health records at each ART clinics, yet 49 and 53 clinical health records were received from the private hospital
and at one of the district hospitals respectively which led to a total of 352 clinical health records to be included in the full data analysis. IQR,
interquartile range.ART treatment, as well as medications prescribed for
opportunistic infections or other comorbidities. All
sensitivity analyses are described in the Supplementary
document, http://links.lww.com/QAD/B143.
Ethics
Ethical approval was obtained from the Ethical Review
Committee on research involving human patients man-
aged by the GHS (ID-number: GHS-ERC 17/11/12).Results
Table 1 shows the baseline characteristics of the ART
clinics and the patients as recorded in the clinical health
records. Among the total of 352 patients included in this
study, 69%were women. The median follow-up time was
32 months in care and 28.5 months after initiating ART.
One-third of the participants initiated ARTwith a CD4þ
cell count of 100 cells/ml or less, whereas approximately
the same proportion had a relatively high CD4þ cell
count at ART initiation (250 cells/ml). No differences
were found in the distribution of CD4þ cell count
categories over the years of treatment initiation (Table 1).
Figure 1 shows the average costs (US$) of care per patient
over time for all patients (black line) and stratified byCD4þ cell count at ART initiation (coloured lines).
During the pre-ART period, the average costs of care per
patient varied considerably both across time and between
CD4þ cell count categories, mostly due to relatively low
numbers of observations. After ART initiation, however,
the costs followed a more consistent pattern. Here, the
average 6-monthly per-patient costs peaked at approxi-
mately 112.6 US$ during the first 6 months and sharply
decreased in the subsequent 6 months to 74.1 US$, a
reduction of 34.2%. During the remaining observational
period, the costs per patient declined more steadily before
ending at 33.9 US$, 4 years after ART initiation (a 70%
decrease in costs compared with the first 6 months)
(Fig. 1).
Figure 2 shows a breakdown of cost components of
treatment and care for HIV-infected people in Ghana by
time in care. Although the costs for ART drugs
comprised 46.1% (51.9 US$) of the overall costs during
the first 6 months on ART, these costs constituted a much
larger part of the total costs of HIV treatment and care
after 4 years on ART (71.7%). Furthermore, the
proportion of the total costs accounting for outpatient
visits declined from 11.3 to 9.6%, for inpatient stays from
3.6 to 0%, for diagnostic tests and routine monitoring
from 3.6 to 1.3% and for non-antiretroviral drugs
prescribed for opportunistic infections or other comor-
bidities from 35.4 to 17.5% over the same 4-year period.
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Fig. 1. Per-patient costs of HIV treatment and care over time in care. The figure shows data from all seven healthcare facilities. It
shows the average costs (US$) of treatment and care per patient at the antiretroviral therapy clinic over time and stratified by CD4þ
cell count at treatment initiation (coloured lines), as well as aggregated across all CD4þ cell count categories (black line). Costs are
presented in 6-monthly periods since treatment initiation, negative time represents preantiretroviral therapy care and the grey
dashed line shows the moment of treatment initiation.Table 2 shows the results of the multivariate linear
regression with individual random effects of 6-monthly
per-patient costs on CD4þ cell count at treatment
initiation, corrected for sex, time on care and healthcare
facility. The lowest costs were found for patients with a
CD4þ cell count of 351 cells/ml or higher, which was
7.9 US$ lower compared with patients with a CD4þ
cell count of 50 cells/ml or less. Nevertheless, the
differences in costs of HIV treatment and care after ART
initiation between the CD4þ cell count categories were
not significant (Table 2).0
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Table 2. Multivariable linear regression of per-patient costs of HIV
treatment and care on CD4R cell count at antiretroviral therapy
initiation in Ghana.
Total costs (US$) (95% CI) P value
Intercept 106.6 (98.2–115.0) <0.0001
CD4þ cell count at ART initiation (cells/ml)
50 0 –
51–100 2.7 (4.9; 10.3) 0.490
101–150 0.2 (8.4; 7.9) 0.953
151–200 0.9 (7.1; 8.8) 0.833
201–250 1.5 (10.1; 7.0) 0.723
251–300 0.7 (8.5; 7.1) 0.867
301–350 1.4 (9.8; 7.0) 0.747
351 7.9 (16.1; 0.3) 0.058
Time after ART initiation (months)
0–5 0 –
6–11 38.5 (43.5; 33.6) <0.0001
12–17 48.0 (53.1; 43.0) <0.0001
18–23 48.8 (54.1; 43.6) <0.0001
24–29 53.8 (59.6; 48.1) <0.0001
30–35 61.6 (68.0; 55.2) <0.0001
36–41 57.3 (64.9; 49.8) <0.0001
42–47 81.5 (93.3; 69.8) <0.0001
Sex
Male 0 –
Female 2.8 (7.5; 1.8) 0.225
Healthcare facility
HF 1 0 –
HF 2 3.3 (11.2; 4.7) 0.418
HF 3 8.8 (0.8; 16.9) 0.031
HF 4 20.0 (12.2; 27.7) <0.0001
HF 5 15.4 (7.4; 23.5) <0.0001
HF 6 4.9 (3.0; 12.8) 0.226
HF 7 15.2 (7.3; 23.2) <0.0001
Model with trends in per-patient costs of 6 months of HIV treatment
and care over CD4þ cell count at treatment initiation, corrected for
time on ART, sex and treatment facility are shown. The regression
model contains individual random effects to control for dependency
of observations in the same individual. ART, antiretroviral therapy; CI,
confidence interval.
Table 3. Change in per patient costs of HIV treatment and care as an
effect of time in care in Ghana.
Time in care (months) Total costs (US$) (95% CI) P value
25 to 30 90.8 (134.4; 47.2) <0.0001
19 to 24 90.0 (114.4; 65.6) <0.0001
13 to 18 68.5 (82.5; 54.5) <0.0001
7 to 12 80.6 (91.1; 70.2) <0.0001
1 to 6 85.3 (90.8; 79.9) <0.0001
0–5 0 –
6–11 38.6 (43.9; 33.2) <0.0001
12–17 48.0 (53.4; 42.5) <0.0001
18–23 50.1 (55.8; 44.5) <0.0001
24–29 56.4 (62.6; 50.1) <0.0001
30–35 64.9 (71.8; 57.9) <0.0001
36–41 60.6 (68.9; 52.3) <0.0001
42–47 84.6 (97.5; 71.7) <0.0001
Multivariable linear regression of per-patient costs of HIV treatment
and care on time since ART initiation in Ghana. Model with trends in
per-patient costs of 6 months of HIV treatment and care, with the first
6 months after ART initiation as the reference period. The regression
model contains individual fixed effects to control for unobserved
time-constant confounding. ART, antiretroviral therapy; CI, confi-
dence interval.analyses, all point-estimates were within the confidence
interval of the main analyses. In addition, none of the
alternative assumptions in the sensitivity analysis changed
the shape of the cost functions over CD4þ cell count of
treatment initiation or time sinceART initiation.All results
and more details of the sensitivity analyses can be found in
the Supplementary document, http://links.lww.com/
QAD/B143.Discussion
We performed a comprehensive analysis of the costs of
treatment and care for HIV-infected patients at ART
clinics in Ghana, and we described cost functions by
CD4þ cell count at initiation and time in care. Our data
show a significant change in overall costs per patient as an
effect of time in care, irrespective of CD4þ cell count at
treatment initiation. The per-patient costs peaked
during the first 6 months after ART initiation at
112.6 US$, and subsequently decreased by about 70%
after 4 years on treatment. The decrease was largelydriven by a decline in medications for opportunistic
infections or other comorbidities.
To our knowledge, this is the first study for any West
African setting to determine cost functions for HIV
treatment and care over time by using longitudinal data,
and the first study from SSA to provide causal cost
functions for HIV treatment and care by time on
treatment. The results from our study are in line with
findings from other studies in SSA, showing that costs for
HIV treatment and care decrease over the course of ART,
largely due to a decline in opportunistic infections,
diagnostic test and routine monitoring and hospitaliza-
tion. However, these studies either only collected cross-
sectional data [15,17,18], analysed longitudinal data
within a limited timeframe of 1–2 years on treatment
[14,19] or only analysed data from private-sector clinics
[16]. Furthermore, none of these studies corrected their
results for unobserved confounding. We performed a
comprehensive, longitudinal data collection of healthcare
utilization over periods of up to 4 years in care, and
performed individual fixed-effects regression analysis to
develop causal and generalizable cost functions by time on
treatment, which will not only be useful for the Ghana
setting, but also can be applied to budgeting and cost-
effectiveness studies throughout SSA.
The findings in this study are of great value for assessing
resource allocation for HIV in Ghana and other SSA
countries in general. Evidence for resource allocation in
HIV treatment is commonly generated by using mathe-
matical modelling, yet so far, most modelling studies
provide projections over time by using one constant cost
value for HIV care after ART initiation [29–31], ignoring
the dynamics of changing costs over time. We show that
healthcare costs for HIV-infected people are dynamic
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resource needs or cost-effectiveness of treatment inter-
ventions should take this into account. Our results show
that costs of treating patients over time decreases after ART
initiation as the health of HIV-infected patients increase,
resulting in decreased need for healthcare utilization. As
ART programmes mature, the patient mix changes and
more and more patients will be relatively symptom-free,
thus requiring less healthcare resources. Consequently, the
overall costs per-patient will decline.
We did not find a significant relationship between CD4þ
cell count at treatment initiation and costs forHIV treatment
and care, even though our data showed slightly decreasing
costs with increasing CD4þ cell counts at initiation. A
possible explanation for this is that case detection inGhana is
still very much driven by symptom-based health seeking
rather than active case finding and regular testing of
asymptomatic HIV-infected people, resulting in selection
bias towards more severely ill patients in our data, regardless
of CD4þ cell count. Another potential reason could be that
the clinical health records from theARTclinics only contain
information on healthcare utilization at the ART clinic. If
we would have been able to also capture healthcare utilized
at other facilities, we might have had more power to detect
differences in costs by CD4þ cell count at treatment
initiation.
There were some limitations to our study. First, patients
in our study were observed for a maximum of 4 years
after treatment initiation, and it is unknown how the cost
of HIV treatment and care would develop for patients on
treatment beyond the time-frame of our study. However,
as treatment costs already started to level off at the end of
the observational period, we believe that further changes
after our observational period are likely to be limited.
Second, as most of the patients in this study had a CD4þ
cell count below 350 cells/ml, it was not possible to
capture costs for patients with higher CD4þ cell counts
at treatment initiation, as recommended by the WHO
[6]. Third, the clinical health records were article-based,
sometimes leading to difficulties in interpreting the data
as well as concerns of missing information. However,
missing information is likely to be random, and therefore
not likely to influence the estimated cost functions. In
addition, local field personnel were included in the data
collection to report as accurate information as possible
about the healthcare utilization. Fourth, several assump-
tions had to be made to translate observed healthcare
utilization and medication uptake into meaningful units
for cost calculations, for instance with regards to
duration of drug prescriptions and staff consultation at
outpatient visits. Although the duration of each
prescription of antiretroviral drugs was based on
recommended follow-up frequency of outpatient visits
in the national guidelines of ART [22], we found that
practice does not always follow guidelines, as many
patients did not visit the health facility according to thefrequency stated in the guidelines. In addition, whereas
the costs of outpatient visits are based on salary of
attending staff, the costs for healthcare personnel may
also include time on other tasks than direct patient
consultation. However, it is reassuring that changes to
these assumptions in the sensitivity analysis did not affect
the main outcomes of the study.
In conclusion, this study showed that the costs of HIV
treatment and care in Ghana reduce substantially during
the course of ART for HIV-infected people. This is the
first detailed cost analysis of HIV treatment and care in
Western Africa and provides important data for policy
makers and researchers when determining resource
needs and cost-effectiveness for HIV treatment and care
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